153 related articles for article (PubMed ID: 35344914)
1. Association of prostate zonal volume with location and aggressiveness of clinically significant prostate cancer: A multiparametric MRI study according to PI-RADS version 2.1.
Yang L; Li M; Zhang MN; Yao J; Song B
Eur J Radiol; 2022 May; 150():110268. PubMed ID: 35344914
[TBL] [Abstract][Full Text] [Related]
2. Cellular density of low-grade transition zone prostate cancer: A limiting factor to correlate restricted diffusion with tumor aggressiveness.
Barral M; Jemal-Turki A; Beuvon F; Soyer P; Camparo P; Cornud F
Eur J Radiol; 2020 Oct; 131():109230. PubMed ID: 32866908
[TBL] [Abstract][Full Text] [Related]
3. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.
Vargas HA; Hötker AM; Goldman DA; Moskowitz CS; Gondo T; Matsumoto K; Ehdaie B; Woo S; Fine SW; Reuter VE; Sala E; Hricak H
Eur Radiol; 2016 Jun; 26(6):1606-12. PubMed ID: 26396111
[TBL] [Abstract][Full Text] [Related]
4. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
5. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
6. Dynamic contrast-enhanced (DCE) MR imaging: the role of qualitative and quantitative parameters for evaluating prostate tumors stratified by Gleason score and PI-RADS v2.
Afshari Mirak S; Mohammadian Bajgiran A; Sung K; Asvadi NH; Markovic D; Felker ER; Lu D; Sisk A; Reiter RE; Raman SS
Abdom Radiol (NY); 2020 Jul; 45(7):2225-2234. PubMed ID: 31549211
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic evaluation of diffusion kurtosis imaging for prostate cancer: Detection in a biopsy population.
Ding K; Yao Y; Gao Y; Lu X; Chen H; Tang Q; Hua C; Zhou M; Zou X; Yin Q
Eur J Radiol; 2019 Sep; 118():138-146. PubMed ID: 31439233
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and grade of malignancy differences with respect to the area of involvement in multiparametric resonance imaging of the prostate in the diagnosis of prostate cancer using the PI-RADS version 2 classification.
Rodríguez-Cabello MA; Méndez-Rubio S; Sanz-Miguelañez JL; Moraga-Sanz A; Aulló-González C; Platas-Sancho A
World J Urol; 2023 Aug; 41(8):2155-2163. PubMed ID: 37326654
[TBL] [Abstract][Full Text] [Related]
9. Optimizing size thresholds for detection of clinically significant prostate cancer on MRI: Peripheral zone cancers are smaller and more predictable than transition zone tumors.
Mahjoub S; Baur ADJ; Lenk J; Lee CH; Hartenstein A; Rudolph MM; Cash H; Hamm B; Asbach P; Haas M; Penzkofer T
Eur J Radiol; 2020 Aug; 129():109071. PubMed ID: 32531720
[TBL] [Abstract][Full Text] [Related]
10. PI-RADS Versions 2 and 2.1: Interobserver Agreement and Diagnostic Performance in Peripheral and Transition Zone Lesions Among Six Radiologists.
Bhayana R; O'Shea A; Anderson MA; Bradley WR; Gottumukkala RV; Mojtahed A; Pierce TT; Harisinghani M
AJR Am J Roentgenol; 2021 Jul; 217(1):141-151. PubMed ID: 32903060
[No Abstract] [Full Text] [Related]
11. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.
Rosenkrantz AB; Babb JS; Taneja SS; Ream JM
Radiology; 2017 Apr; 283(1):119-129. PubMed ID: 27783538
[TBL] [Abstract][Full Text] [Related]
12. Morphometric analysis of prostate zonal anatomy using magnetic resonance imaging: impact on age-related changes in patients in Japan and the USA.
Matsugasumi T; Fujihara A; Ushijima S; Kanazawa M; Yamada Y; Shiraishi T; Hongo F; Kamoi K; Okihara K; de Castro Abreu AL; Oishi M; Shin T; Palmer S; Gill IS; Ukimura O
BJU Int; 2017 Oct; 120(4):497-504. PubMed ID: 28220583
[TBL] [Abstract][Full Text] [Related]
13. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
14. Inter-Reader Variability Using PI-RADS v2 Versus PI-RADS v2.1: Most New Disagreement Stems from Scores 1 and 2.
Beetz NL; Haas M; Baur A; Konietschke F; Roy A; Hamm CA; Rudolph MM; Shnayien S; Hamm B; Cash H; Asbach P; Penzkofer T
Rofo; 2022 Aug; 194(8):852-861. PubMed ID: 35545106
[TBL] [Abstract][Full Text] [Related]
15. A Single-Arm, Multicenter Validation Study of Prostate Cancer Localization and Aggressiveness With a Quantitative Multiparametric Magnetic Resonance Imaging Approach.
Maas MC; Litjens GJS; Wright AJ; Attenberger UI; Haider MA; Helbich TH; Kiefer B; Macura KJ; Margolis DJA; Padhani AR; Selnæs KM; Villeirs GM; Fütterer JJ; Scheenen TWJ
Invest Radiol; 2019 Jul; 54(7):437-447. PubMed ID: 30946180
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of diffusion-weighted imaging for prostate cancer: Peripheral zone versus transition zone.
Lee H; Hwang SI; Lee HJ; Byun SS; Lee SE; Hong SK
PLoS One; 2018; 13(6):e0199636. PubMed ID: 29933396
[TBL] [Abstract][Full Text] [Related]
17. DCE-MRI of the prostate using shutter-speed vs. Tofts model for tumor characterization and assessment of aggressiveness.
Hectors SJ; Besa C; Wagner M; Jajamovich GH; Haines GK; Lewis S; Tewari A; Rastinehad A; Huang W; Taouli B
J Magn Reson Imaging; 2017 Sep; 46(3):837-849. PubMed ID: 28092414
[TBL] [Abstract][Full Text] [Related]
18. Predictive power of the ESUR scoring system for prostate cancer diagnosis verified with targeted MR-guided in-bore biopsy.
Schimmöller L; Quentin M; Arsov C; Hiester A; Kröpil P; Rabenalt R; Albers P; Antoch G; Blondin D
Eur J Radiol; 2014 Dec; 83(12):2103-2108. PubMed ID: 25241051
[TBL] [Abstract][Full Text] [Related]
19. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
[TBL] [Abstract][Full Text] [Related]
20. Postoperative Biochemical Failure in Patients With PI-RADS Category 4 or 5 Prostate Cancers: Risk Stratification According to Zonal Location of an Index Lesion.
Shin N; Park SY
AJR Am J Roentgenol; 2020 Oct; 215(4):913-919. PubMed ID: 32755167
[No Abstract] [Full Text] [Related]
[Next] [New Search]
